Remicade and Humira are monoclonal antibodies that target TNF-alpha. Remicade's source is chimeric (not from a human), whereas Humira's source is human. The GI probably knows that Humira is worth skipping (maybe thinks that anything that targets TNF-alpha would trigger lupus again?). Remicade has 0.6% adverse reports of lupus like syndrome, whereas Humira has 0.07% adverse reports of lupus like syndrome (this, according to druginformer.com). Cizma (aka certolizuman pegol) also targets TNF-alpha, but is a fragment, not a full antibody (no report on druginformer).
Entyvio (aka vedolizuman) is also a monoclonal antibody, but it targets integrin alpha4 beta7 (not TNF-alpha). The source is not human, but has been 'humanized' (no report on druginformer.com).